Lakefront Biotherapeutics NV (LKFT)
Lakefront Biotherapeutics is a Belgian biotechnology company developing medicines for serious immune and inflammatory diseases. It last closed at $34.39 on Nov 17, down 1.15% on the day. The average 12-month price target from 2 analysts is $36.00 (+4.7% from the last close), with a high of $45.00 and a low of $27.00. In the past 30 days there were 1 dark pool print totaling $790K, the largest $790K.
Key Stats
Fiscal 2025Not reported for this period.
From LKFT's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 26). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on LKFT in the past 90 days. The average target is $36.00, with a high of $45.00 and a low of $27.00, compared with the last close of $34.39.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Morgan Stanley | Target raised | Hold | $26 → $27 |
| Sep 23 | RBC Capital | Upgrade | Buy | $26 → $45 |
| Aug 11 | Morgan Stanley | Maintained | Hold | $26 |
| Aug 11 | RBC Capital | Maintained | Hold | $26 |
Technical Analysis
The stock is 5% above its 20 day and 11% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 70), overbought. The nearest support is the Pivot S1 at $34.12, and the nearest resistance the swing high (Nov 5) at $34.49.
| RSI (14) | 70.11 | Overbought above 70 | Overbought |
| MACD | 1.09 | Above its signal line | Bullish |
| Stochastic | 71.1 | Middle of its range | Neutral |
| ADX (14) | 29.6 | Trending up | |
| Williams %R | -31.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 118.1 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +7.0% | Change over 10 sessions | Bullish |
| ATR (14) | $0.92 | Typical daily range, 2.7% of price |
| RSI (14) | 70.08 | Overbought above 70 | Overbought |
| MACD | 1.02 | Above its signal line | Bullish |
| Stochastic | 85.9 | Near the top of its range | Overbought |
| ADX (14) | 24.4 | Weak trend | |
| Williams %R | -12.9 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 190.0 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +28.3% | Change over 10 sessions | Bullish |
| ATR (14) | $1.90 | Typical daily range, 5.5% of price |
What happened before
See how LKFT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LKFT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
Whale Options Flow
90DNo whale options trades in LKFT in the last 90 days.
Dark Pool
30DLKFT Institutional Ownership
Full report →- ▲57 buying vs 30 selling
- ▲Shares held by funds +4.7%
- ▲Funds holding +16
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 95 | 79 | +20.3% |
| In funds' top 10 | 4 | 5 | −20.0% |
| Held by funds | – | – | – |
| New / increased | 22 / 35 | 11 / 26 | +54.1% |
| Reduced / sold out | 23 / 7 | 28 / 21 | −38.8% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LKFT is in one of them and how their past LKFT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LKFT in an article yet. Here's the latest on the wider market.
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics is a biotechnology company based in Mechelen, Belgium, that develops medicines for patients with serious diseases. Its main focus is immunology, where its lead candidate is an oral medicine being studied in lupus and dermatomyositis, two autoimmune conditions. The company has also decided to wind down its cell therapy work in cancer and is seeking new business development deals to advance its remaining drug candidates.
- Headquarters
- 2800 Mechelen
- Founded
- 1999
- Website
- glpg.com ↗



